Psychedelics Like Psilocybin, MDMA Tied to Higher Odds for Schizophrenia
By Dennis Thompson HealthDay Reporter
WEDNESDAY, Nov. 13, 2024 -- People are at higher risk of schizophrenia if they indulge in psychedelic drugs, a new study warns.
Patients who land in the ER following hallucinogen use have a 21-fold higher risk of developing schizophrenia compared to the general population, Canadian researchers report.
Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased risk of schizophrenia after ER treatment for psychedelic use.
Hallucinogens include drugs like psilocybin, LSD, DMT (Ayahuasca) and MDMA (Ecstasy).
“Our findings underscore a concerning link between hallucinogen use that requires care in the emergency room and increased risk of schizophrenia,” said investigator Dr. Daniel Myran, research chair in social accountability at the University of Ottawa.
“While there is enormous enthusiasm for psychedelic-assisted therapy as a new mental health treatment, we need to remember how early and limited the data remains for both the benefits and the risks,” Myran added in a university news release.
For the study, researchers analyzed health data for more than 9.2 million people ages 14 to 65 living in Ontario between 2008 and 2021.
Researchers looked at emergency room visits involving hallucinogens, and whether patients had been diagnosed with schizophrenia afterward.
Overall, annual rates of ER visits involving hallucinogens increased by 86% between 2014 and 2021, after remaining stable from 2008 to 2012, results show.
About 4% of people were diagnosed with schizophrenia within three years of an ER visit involving hallucinogens, researchers found. By comparison, only 0.15% of the general population developed schizophrenia during the study period.
People with ER visits for psychedelics also were more likely to develop schizophrenia than those who visited the ER due to alcohol (4.7 times greater) or cannabis (1.5 times greater).
However, researchers noted that the findings cannot prove a cause-and-effect link between hallucinogen use and schizophrenia, and that more study is needed to better understand this relationship.
“Clinical trials of psychedelic-assisted psychotherapy have safeguards, such as excluding individuals with a personal or family history of schizophrenia and close monitoring while participants use hallucinogens,” Myran said. “Our findings provide a timely caution about potential risks of hallucinogen use outside of trial settings.”
The researchers also noted it’s important that ER doctors treating patients who’ve used psychedelics be aware of the mental health risks these folks face.
The new study was published Nov. 13 in the journal JAMA Psychiatry.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-14 06:00
Read more
- Phase 2 study demonstrates the first successful clinical application of antifibrotic therapy for breast cancer
- Gene Therapy Might Tweak Fats, Help Prevent Arthritis in Overweight Kids
- More Than One-Third Have ED Visit Within 90 Days Before Cancer Diagnosis
- Monthly News Roundup - October 2024
- Acupuncture Reduces Pain With Chronic Sciatica From Herniated Disk
- Women Can Incur 'Catastrophic' Bills for Out-of-State Abortions, Study Finds
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions